Bessemer Group’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History

Bessemer Group’s Portfolio STAB Stock Details STAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-425	Closed	–	–	2029
2018 Q4	$0	Buy	+425	New	+$734	﹤0.01%	2090

Other funds holding STAB

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Bessemer Group's STAB Position: Q1 2019 in Review

Bessemer Group sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q1 2019, closing a stake of 425 shares.

Bessemer Group first reported a position in STAB in Q4 2018 and held it in 1 quarter. The position peaked at $0 in Q4 2018. 12 funds tracked by Wall St. Rank hold STAB as of Q1 2019.

Bessemer Group reported no remaining Statera Biopharma, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
Bessemer Group sold 425 Statera Biopharma, Inc. Common Stock shares in Q1 2019.
Bessemer Group first reported a position in Statera Biopharma, Inc. Common Stock in Q4 2018 and held it in 1 quarter.
Bessemer Group's Statera Biopharma, Inc. Common Stock position peaked at $0 in Q4 2018.
12 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q1 2019.

Based on Bessemer Group's 13F filing for Q1 2019, filed 13 May 2019.